Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
Document and Entity Information - USD ($) $ in Thousands	Dec. 31, 2015	Feb. 24, 2016	Jun. 30, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	Semler Scientific, Inc.
Entity Central Index Key	0001554859
Trading Symbol	smlr
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding		5,123,568
Entity Public Float			$ 9,243,653
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Amendment Flag	false
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	FY

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current Assets:
Cash	$ 405	$ 4,156
Restricted cash		2,100
Trade accounts receivable, net of allowance for doubtful accounts of $183 and $51 respectively	1,278	355
Prepaid expenses and other current assets	69	135
Total current assets	1,752	6,746
Assets for lease, net	830	673
Property and equipment, net	497	9
Long-term deposits		17
Deferred financing costs		55
Total assets	3,079	7,500
Current liabilities:
Accounts payable	839	89
Accrued expenses	2,317	1,363
Deferred revenue	952	612
Loans payable, current portion		2,000
Total current liabilities	4,108	4,064
Long-term liabilities:
Deferred rent	43
Total long-term liabilities	43
Stockholders' equity (deficit):
Common stock, $0.001 par value; 50,000,000 shares authorized; 5,148,568, and 4,741,017 shares issued, and 5,123,568 and 4,716,017 shares outstanding (treasury shares of 25,000 and 25,000, respectively)	5	5
Additional paid-in capital	21,291	17,298
Accumulated deficit	(22,368)	(13,867)
Total stockholders' equity (deficit)	(1,072)	3,436
Total liabilities and stockholders' equity (deficit)	$ 3,079	$ 7,500

Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Allowance for doubtful accounts on trade accounts receivable (in dollars)	$ 183	$ 51
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	5,148,568	4,741,017
Common stock, shares outstanding	5,123,568	4,716,017
Treasury stock, shares	25,000	25,000

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
Statements of Operations - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Revenue	$ 7,001	$ 3,635
Total Revenue	7,001	3,635
Operating expenses:
Cost of revenue	2,847	692
Engineering and product development	1,436	1,113
Sales and marketing	6,266	3,723
General and administrative	4,871	2,448
Total operating expenses	15,420	7,976
Loss from operations	(8,419)	(4,341)
Other expense:
Interest expense	(74)	(175)
Other expense	(8)	1
Other expense	(82)	(174)
Net loss attributable to common stockholders	$ (8,501)	$ (4,515)
Net loss per share, basic and diluted (in dollars per share)	$ (1.72)	$ (1.10)
Weighted average number of shares used in computing basic and diluted loss per share (in shares)	4,928,881	4,105,754

Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Convertible preferred stock Series A	Convertible preferred stock Series A-1	Convertible preferred stock Series A-2	Common Stock	Treasury stock	Additional Paid-in Capital	Accumulated deficit	Total
Balance at Dec. 31, 2013	$ 6,020	$ 482	$ 208	$ 1		$ 2,346	$ (9,352)	$ (295)
Balance (in shares) at Dec. 31, 2013	1,468,402	293,750	250,000	811,750	(25,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of all Preferred classes to common stock in IPO	$ (6,020)	$ (482)	$ (208)	$ 3		6,707
Conversion of all Preferred classes to common stock in IPO (in shares)	(1,468,402)	(293,750)	(250,000)	2,491,267
IPO funding				$ 1		10,010		10,010
IPO funding (in shares)				1,430,000
Offering costs						(1,959)		(1,959)
Stock option exercise						4		$ 4
Stock option exercise (in shares)				8,000				8,000
Stock-based compensation						190		$ 190
Net loss							(4,515)	(4,515)
Balance at Dec. 31, 2014				$ 5		17,298	(13,867)	3,436
Balance (in shares) at Dec. 31, 2014				4,741,017	25,000
Balance at Jan. 01, 2015				$ 5		17,298	(13,867)	3,436
Balance (in shares) at Jan. 01, 2015				4,741,017	(25,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common Stock private placements						1,374		1,374
Common Stock private placements (in shares)				400,500
Stock option exercise						14		$ 14
Stock option exercise (in shares)				7,051				7,051
Stock-based compensation						2,605		$ 2,605
Net loss							(8,501)	(8,501)
Balance at Dec. 31, 2015						$ 21,291	$ (22,368)	$ (1,072)
Balance (in shares) at Dec. 31, 2015				5,148,568	(25,000)

Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
Statements of Cash Flows - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$ (8,501)	$ (4,515)
Reconciliation of Net Loss to Net Cash Used in Operating Activities:
Amortization of deferred financing costs	55	147
Depreciation	315	196
Loss on disposal of assets for lease	144	78
Allowance for doubtful accounts	272	128
Stock-based compensation expense	2,605	190
Changes in Operating Assets and Liabilities:
Trade accounts receivable	(1,195)	(255)
Prepaid expenses and other current assets	83	(106)
Accounts payable	750	(167)
Accrued expenses	997	236
Deferred revenue	340	246
Net Cash Used in Operating Activities	(4,135)	(3,822)
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment	(532)	(9)
Change in restricted cash	2,100	(2,100)
Purchase of assets for lease	(572)	(432)
Net Cash Provided by (Used in) Investing Activities	996	(2,541)
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of common stock	1,374	10,010
Proceeds from stock option exercise	14	4
Offering costs		(1,959)
Proceeds from loans payable		2,000
Payments of loans payable	(2,000)	(158)
Payments of equipment leases		(112)
Net Cash Provided by (Used in) Financing Activities	(612)	9,785
INCREASE (DECREASE) IN CASH	(3,751)	3,422
CASH, BEGINNING OF PERIOD	4,156	734
CASH, END OF PERIOD	405	4,156
Cash paid for income taxes		1
Cash paid for interest	$ 19	28
Supplemental disclosure of noncash financing activity:
Conversion of preferred stock to common stock		$ 6,707

The Company

12 Months Ended

Dec. 31, 2015

Company [Abstract]

The Company

The Company

Semler Scientific, Inc. (the “Company”) was incorporated in the State of Oregon on August 9, 2007, established C-corporation status in 2012, and reincorporated as a Delaware corporation during 2013. The Company is an emerging growth company providing technology solutions to improve the clinical effectiveness and efficiency of healthcare insurers and physician groups. Its innovative and proprietary products and services assist its customers in evaluating and treating chronic diseases. In 2011, the Company began commercializing its first patented and U.S. Food and Drug Administration (“FDA”) cleared product, which measured arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease (“PAD”). In March 2015, the Company received FDA 510(k) clearance for the next generation version of its product, QuantaFlo™, which the Company commercially launched in August 2015. In April 2015, the Company launched its multi-test service platform, WellChec™, to more comprehensively evaluate its customers’ patients for chronic disease. The Company has one operating segment and generates revenue domestically primarily through direct licensing to direct customers. The Company is based in Portland, Oregon.

Going Concern

12 Months Ended

Dec. 31, 2015

Going Concern [Abstract]

Going Concern

2.	Going Concern

The Company has incurred recurring losses since inception and expects to continue to incur losses as a result of costs and expenses related to the Company’s marketing and other promotional activities, research and continued development of its product. As of December 31, 2015, the Company has negative working capital of $2,356, cash of $405 and stockholders’ deficit of $1,072. The Company’s principal sources of cash have included the issuance of equity securities, and to a lesser extent, borrowings under loan agreements and revenue from leasing its product. To increase revenues, the Company’s operating expenses will continue to grow and, as a result, the Company will need to generate significant additional revenues to achieve profitability.

The Company’s financial statements as of December 31, 2015 have been prepared under the assumption that the Company will continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to attain further operating efficiencies and, ultimately, to generate additional revenue. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company can give no assurances that additional capital that the Company is able to obtain, if any, will be sufficient to meet the Company’s needs. The foregoing conditions raise substantial doubt about the Company’s ability to continue as a going concern.

Summary of Significant Accounting Policies and Estimates

12 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Summary of Significant Accounting Policies and Estimates

Summary of Significant Accounting Policies and Estimates

Basis for Presentation

The Company’s financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Initial Public Offering

In February 2014, the Company completed its initial public offering (“IPO”) in which it issued and sold 1,430,000 shares of its common stock at a public offering price of $7.00 per share. The Company received net proceeds of $7,403 after deducting underwriting discounts and commissions of $848 and other offering expenses of approximately $1,759. The Company incurred $648 of the offering expenses in 2013, and incurred $1,959 of such expenses in the first quarter of 2014. The Company granted the underwriter an option to acquire an additional 214,500 shares of its common stock, which expired April 6, 2014 unexercised, and issued the underwriter warrants to acquire an aggregate of 71,500 shares of its common stock at an exercise price of $8.75 per share, which become exercisable February 20, 2015 and expire February 20, 2019. Upon the closing of the IPO, all shares of the Company’s then-outstanding Series A convertible Preferred Stock (1,468,402), Series A-1 convertible Preferred Stock (293,750) and Series A-2 convertible Preferred Stock (250,000) automatically converted into an aggregate of 2,012,152 shares of common stock. In addition, the Company’s then outstanding warrants to acquire an aggregate of 1,067,210 shares of Series A convertible Preferred Stock and 228,656 shares of Series A-1 convertible Preferred Stock were cashlessly exercised at the IPO price for an aggregate of 479,115 shares of common stock. All other outstanding warrants of the Company became exercisable for common stock effective upon the IPO in accordance with their terms.

Use of Estimates

The preparation of the accompanying financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses, and related disclosures during the reporting period. Significant items subject to such estimates include revenue recognition, legal contingencies, allowance for doubtful accounts, valuation of equipment on lease, deferred tax asset valuation allowance, stock-based compensation and valuation of warrants, common and convertible preferred stock. These estimates and assumptions are based on management’s best estimates and judgment. Management regularly evaluates its estimates and assumptions using historical experience and other factors; however, actual results could differ significantly from these estimates.

Revenue Recognition

The Company generates revenue primarily from the rental or license of its vascular testing product, or providing diagnostic testing service to its customers. The Company recognizes revenue from the licensing of its vascular testing product pursuant to agreements that typically automatically renew each month with revenue recognized on a daily convention basis. The Company's arrangements with customers for its vascular testing product are normally on a month-to-month basis with fees billed at the rates established in the customer agreement. The Company recognizes revenue for providing diagnostic testing services on a per test basis to customers, as earned.

Restricted Cash

On September 30, 2014 the Company entered into a revolving credit line with First Republic Bank. Per the terms of this line of credit, the Company is required to keep a collateral cash account open with First Republic Bank. The cash balance of this collateral cash account must be a minimum of 105% of the total principal balance outstanding on the line of credit. As of December 31, 2015, the line of credit has been repaid.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are recorded at the invoiced amount, net of allowances for doubtful accounts. The allowance for doubtful accounts is based on management’s assessment of the collectability of accounts. The Company regularly reviews the adequacy of this allowance for doubtful accounts by considering historical experience, the age of the accounts receivable balances, the credit quality of the customers, current economic conditions, and other factors that may affect customers’ ability to pay to determine whether a specific allowance is appropriate. Accounts receivable deemed uncollectable are charged against the allowance for doubtful accounts when identified.

Assets for Lease

Assets for lease are recorded at cost. At December 31, 2015 and 2014, assets for lease consisted of vascular testing devices, which are leased to customers. The cost of such assets for lease is depreciated on a straight-line basis over 36 months for the units outstanding and recorded as cost of revenue.

The Company regularly reviews whether facts and circumstances exist which indicate that the carrying amounts of assets, may not be recoverable or that the useful life of assets are shorter or longer than originally estimated. The Company assesses the recoverability of its assets by comparing the projected undiscounted net cash flows associated with the related asset over their estimated remaining lives against their respective carrying amounts. The Company considers factors such as estimated usage and expected lives of its assets for lease in this analysis. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. At December 31, 2015 and 2014, there were no impairment indicators.

Property and Equipment

Capital assets are recorded at cost. The cost of such capital assets is depreciated on a straight-line basis over a term depending on the assigned category (described below) and recorded as cost of revenue for WellChec capital assets and depreciation for all other capital assets.

At December 31, 2015 and 2014, capital assets are classified into one of the following categories:

	Category Name	Description
	Machinery & Equipment	Manufacturing, R&D, or other non-office equipment
	Computer Equipment & Software	Software, computers, monitors, printers and other related equipment.
	Furniture & Fixtures	Office equipment and furniture owned by the company

At December 31, 2015 and 2014, capital assets are depreciated based on the following assumed useful life for each category:

	Account Name	Useful Life
	Machinery & Equipment	Five years
	Computer Equipment & Software	Three years
	Furniture & Fixtures	Five years

The Company regularly reviews whether facts and circumstances exist that indicate that the carrying amounts of capital assets, may not be recoverable or that the useful life of assets are shorter or longer than originally estimated. The Company assesses the recoverability of its assets by comparing the projected fair value of the related asset over the estimated remaining life against the respective carrying amounts. The Company considers factors such as estimated usage and expected lives of its capital assets in this analysis. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. At December 31, 2015 and 2014, there were no impairment indicators.

Fair Value of Financial Instruments

Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of the fair value hierarchy under FASB Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, are described as follows:

Level 1 — Unadjusted quoted prices in active markets for identical assets or liabilities;

Level 2 — Inputs other than quoted prices included in Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data; and

Level 3 — Unobservable inputs that are supported by little or no market activity, which requires the Company to develop its own models.

The financial instruments of the Company consist primarily of cash, accounts receivable, accounts payable, and loans payable of the Company. The carrying amounts of these items are considered a reasonable estimate of fair value at December 31, 2015 and 2014 due to their short term nature and their market interest rates, which represents level 2 valuations.

Deferred Revenue

Deferred revenue represents amounts billed to or collected from customers for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The full amount is expected to be recognized as revenues within one year from the balance sheet date and, therefore, such deferred amounts have been classified as current liabilities in the balance sheets presented. The Company generally invoices its clients in advance of a rental period with payment due upon receipt of the invoice.

Deferred Financing Costs

In 2011, certain of the Company’s Directors personally guaranteed various loans or leases for the Company from First Republic Bank and U.S. Bancorp Business Equipment Finance Group, see Note 8. In consideration for the personal guarantees, these directors were given the opportunity to purchase fully vested warrants exercisable for common stock, which were determined to have a fair value of $425 at issuance. The deferred financing costs are the fair value of the related warrants less the purchase price of the warrants. These financing costs were deferred and were being amortized over the term of the loan or lease obligation. The amount amortized to interest expense was $55 and $147 in 2015 and 2014, respectively. The leases were paid off early due to the opening of a new line of credit, resulting in acceleration of the expensing of the outstanding deferred financing costs in 2014. See Note 8.

Research and Development

The Company expenses costs related to the research and development associated with the design, development, testing and enhancement of its products and services. Such expenses include salaries and related employee benefits, and fees paid to external service providers.

Stock-Based Compensation

Stock-based compensation expense is measured based on the grant-date fair value of the stock-based awards. The Company recognizes stock-based compensation expense for the portion of each option grant or stock award that is expected to vest over the estimated period of service and vesting. The estimation of the fair value of each stock-based grant on the date of grant involves numerous assumptions by management. The Company uses the Black-Scholes option pricing model as the method for determining the estimated grant-date fair value of stock options. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of stock-based awards, including the option’s expected volatility and the price of the underlying stock. In addition, the Company

estimates the forfeiture rate of such awards during the requisite service period. Stock-based compensation expense is recognized on a straight-line basis over the requisite service period of the grant.

Employee Benefit Plan

The Company has a savings plan that qualifies under Section 401(k) of the Internal Revenue Code. There were no matching or discretionary employer contributions made to this plan during the years ended December 31, 2015 and 2014.

Income Taxes

The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are recognized for the expected tax consequences attributable to the differences between financial reporting and the tax bases of existing assets and liabilities and operating loss carry forwards, and they are measured using enacted tax rates expected to be in effect when differences are expected to reverse. A valuation allowance is recorded for loss carry-forwards and other deferred tax assets where it is more likely than not that such loss carry-forward and deferred tax asset will not be realized. The estimate for the valuation allowance for deferred tax assets requires management to make significant estimates and judgments about projected future operating results. If actual results differ from these projections or if management’s expectations of future results change, it may be necessary to adjust the valuation allowance.

Presentation of Prior Year Data

Certain reclassifications have been made to conform prior year data to the current presentation.

Net Loss per Share

Basic and diluted net loss per common share is calculated by dividing the net loss attributable to common stockholders by dividing the weighted-average number of common shares outstanding during the periods, respectively, without consideration for outstanding common stock equivalents because their effect would have been anti-dilutive. Common stock equivalents are included in the calculation of diluted earnings per common share only if their effect is dilutive. For the periods presented, the Company’s outstanding common stock equivalents consisted of options and warrants to purchase shares of common stock, all of which are antidilutive, and therefore were not included in the calculation for diluted loss per share.

Excise Tax Liability on Medical Devices

Recognition of the excise tax liability falls under ASC 450, Contingencies, because the tax is assessed on revenues. The Company recognizes the excise tax when a rental payment is invoiced. Based on the guidance in ASC 605-45-50-3 and 50-4, these excise taxes are presented on a gross basis, included in general and administrative expenses. The excise tax is not an income tax.

Assets for lease, net

12 Months Ended

Dec. 31, 2015

Leases, Capital [Abstract]

Assets for lease, net

4.	Assets for lease, net

Assets for lease consist of the following:

	As of December 31,
	2015			2014
Assets for lease	$	1,280		$	956
Less: accumulated depreciation		(450	)		(283	)
Assets for lease, net	$	830		$	673

Depreciation expense amounted to $271 and $194 for the years ended December 31, 2015 and 2014, respectively. Reduction to accumulated depreciation for returned items was $104 and $87 for the years ended December 31, 2015 and December 31, 2014, respectively.

Property and Equipment, net

12 Months Ended

Dec. 31, 2015

Property, Plant and Equipment [Abstract]

Property and Equipment, net

Property and Equipment, net

Capital assets consist of the following:

	As of December 31,
	2015			2014
Capital assets	$	542		$	13
Less: accumulated depreciation		(45	)		(4	)
Capital assets, net	$	497		$	9

Depreciation expense amounted to $44 and $2 for the years ended December 31, 2015 and 2014, respectively.

Concentration of Credit Risk

12 Months Ended

Dec. 31, 2015

Risks and Uncertainties [Abstract]

Concentration of Credit Risk

7.	Concentration of Credit Risk

Credit risk is the risk of loss from amounts owed by the financial counterparties. Credit risk can occur at multiple levels; as a result of broad economic conditions, challenges within specific sectors of the economy, or from issues affecting individual companies. Financial instruments that potentially subject the Company to credit risk consist of cash and accounts receivable.

The Company maintains cash with major financial institutions. The Company’s cash consist of bank deposits held with banks that, at times, exceed federally insured limits. The Company limits its credit risk by dealing with counterparties that are considered to be of high credit quality and by performing periodic evaluations of the relative credit standing of these financial institutions.

Concentration of credit risk with respect to accounts receivable is limited due to the large number of customers comprising the payer base. Management periodically monitors the creditworthiness of its customers and believes that it has adequately provided for any exposure to potential credit loss. Two customers accounted for 14.2% and 11.8% of revenue, respectively, in the year ended December 31, 2015, and 12.9% and 11.7%, respectively, in 2014. For the years ended December 31, 2015 and 2014, there were two customers representing 18.6% and 11.7% of invoicing, respectively, in 2015, and 19.8% and 12.1% of invoicing, respectively, in 2014. As of December 31, 2015 and 2014, there were customers with accounts receivable balances of 19.4% and 13.3%, respectively, in 2015, and 31.4%, 13.2% and 10.3%, respectively, in 2014.

The Company maintains a reserve against its accounts receivable equivalent to the ending balance 90 days or greater. As of December 31, 2015 and 2014 the reserve was $183 and $51, respectively.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

8.	Commitments and Contingencies

Facilities Leases

For the year ended December 31, 2015, the Company recognized $209 in facilities lease expense. The Company had no material facilities leases for the year ended December 31, 2014 and had no rent expense for such period.

On September 23, 2014, the Company entered into a 36-month lease agreement for office space for the sales and marketing team located in Menlo Park, CA. The lease term commenced February 1, 2015 and is effective through January 31, 2018. Payments required under the terms of the lease are $17.0 per month from February 2015 to January 2016, $17.5 per month from February 2016 to January 2017, and $18.0 per month from February 2017 to January 2018. The Company anticipates total future lease payments of $209.1 for the year ended December 31, 2016; $215.4 for the year ended December 31, 2017; and $18.0 for the year ended December 31, 2018. On July 15, 2015, the Company entered into a 30-month sublease agreement for the Menlo Park office space, which commenced August 1, 2015 and is effective through the term of the lease, January 31, 2018. Payments required to the Company under the terms of the sublease are $15.5 per month from August 2015 to July 2016, $16.0 per month from August 2016 to July 2017, and $16.5 per month from August 2017 to January 2018. The Company anticipates receipt of total future sublease payments of $188.6 for the year ended December 31, 2016; $194.4 for

the year ended December 31, 2017; and $16.5 for the year ended December 31, 2018. The Company recorded an expense of $50, which represented the difference between estimated cash payments on the lease and cash receipts from the sublease. The Company recorded the resulting long-term liability as accrued rent on the Company’s balance sheet. The cease use date is July 31, 2015.

Equipment Leases and Loans Payable

On February 9, 2011, the Company entered into an Equipment Finance Agreement with U.S. Bancorp Business Equipment Finance Group. Pursuant to the agreement, the Company obtained a $39 secured loan for a 48-month term that had an annual fixed interest rate of 13%. The loan was secured by the related leased equipment. Under the agreement, the Company made monthly payments consisting of $1 of principal plus any accrued interest. The agreement provided for customary events of default. This loan was personally guaranteed by a Company director and a principal stockholder of the Company. This facility was retired in September 2014.

On May 27, 2011, the Company entered into an Equipment Finance Agreement with U.S. Bancorp Business Equipment Finance Group. Pursuant to the Agreement, the Company obtained a $109 secured loan for a 60-month term that had an annual fixed interest rate of 6%. The loan was secured by the related leased equipment. Under the Agreement, the Company made monthly payments consisting of $2 of principal plus any accrued interest. The Agreement provided for customary events of default. This loan was personally guaranteed by a Company director and a principal stockholder of the Company. This facility was retired in September 2014.

At various dates in 2011, the Company entered into Lease Agreements with Lease Corporation of America. Pursuant to these agreements, the Company obtained an aggregate amount of $66 for a 60-month term that had variable annual interest rates of approximately 14%. The leases were secured by the related leased equipment. Under the agreements, the Company made monthly payments of approximately $1 of principal plus any accrued interest. The agreements provided for customary events of default. The leases were personally guaranteed by a principal stockholder of the Company. This facility was retired in September 2014.

On June 17, 2011, the Company entered into a loan agreement with First Republic Bank. Pursuant to the loan agreement, the Company obtained a $150 secured loan for a 60-month term that had a variable interest rate based on First Republic’s Prime plus a spread of 1.75% p.a. and a floor of 3.25% p.a. The initial interest rate was 5% p.a. Under the loan agreement, the Company made monthly payments consisting of $3 of principal plus any accrued interest. The loan agreement provided for customary events of default. This loan was personally guaranteed by a principal stockholder of the Company. This loan agreement was retired in September 2014.

On September 13, 2011, the Company entered into an additional loan agreement with First Republic Bank. Pursuant to the loan agreement, the Company obtained a $150 loan for a 60-month term that had a variable annual interest rate based on First Republic’s Prime plus a spread of 1.75% and a floor of 3.25%. The initial interest rate was 5%. Under the loan agreement, the Company made monthly payments consisting of $3 of principal plus any accrued interest. The loan agreement provided for customary events of default. This loan was personally guaranteed by a principal stockholder of the Company. This loan agreement was retired in September 2014.

On September 30, 2014, the Company entered into a revolving line of credit with First Republic Bank. Pursuant to the line of credit agreement, the Company could borrow up to $2,000 for a 12-month term that had a variable annual interest rate based on First Republic’s Prime less a spread of 2.0% p.a. The initial interest rate was 1.25% p.a. Under the line of credit agreement, the Company made monthly payments consisting of $2 of interest, and an annual payment consisting of $2,002 principal plus any accrued interest. The line of credit agreement provided for customary events of default. This line of credit was secured by a $2,100 collateral cash account in the Company’s name at First Republic. The line of credit was retired and the collateral cash account was closed in September 2015.

Interest expense under these obligations for the year ended December 31, 2015 and 2014 was $19 and $28, respectively.

Indemnification Obligations

The Company enters into agreements with customers, partners, lenders, consultants, lessors, contractors, sales representatives and parties to certain transactions in the ordinary course of the Company’s business. These agreements may require the Company to indemnify the other party against third party claims alleging that its product infringes a patent or copyright. Certain of these agreements require the Company to indemnify the other party against losses arising from: a breach of representations or covenants, claims relating to property damage, personal injury or acts or omissions of the Company, its employees, agents or representatives. The Company has also agreed to indemnify the directors and certain of the officers and employees in accordance with the by-laws of the Company. These indemnification provisions will vary based upon the nature and terms of the agreements. In many cases, these indemnification provisions do not contain limits on the Company’s liability, and the occurrence of contingent events that will trigger payment under these indemnities is difficult to predict. As a result, the Company cannot estimate its potential liability under these indemnities. The Company believes that the likelihood of conditions arising that would trigger these indemnities is remote and, historically, the Company had not made any significant payment under such indemnification provisions. Accordingly, the Company has not recorded any liabilities relating to these agreements. In certain cases, the Company has recourse against third parties with respect to the aforesaid indemnities, and the Company believes it maintains adequate levels of insurance coverage to protect the Company with respect to potential claims arising from such agreements.

Stockholders' Equity (Deficit)

12 Months Ended

Dec. 31, 2015

Stockholders' Equity Note [Abstract]

Stockholders' Equity (Deficit)

9.	Stockholders’ Equity (Deficit)

Authorized Capital

In connection with the conversion to a Delaware corporation, during the quarter ended September 30, 2013, the Company’s certificate of incorporation was amended and restated to authorize the Company to issue up to 54,000,000 shares, of which 50,000,000 shares were designated as common stock with par value of $0.001 per share and 4,000,000 shares were designated as convertible preferred stock with par value of $0.001 par value per share. The authorized preferred stock for all periods presented is as follows: (i) 2,800,000 shares of Series A convertible Preferred Stock, (ii) 800,000 shares of Series A-1 convertible Preferred Stock, and (iii) 400,000 shares of Series A-2 convertible Preferred Stock.

Common Stock

Issuance of Common Stock

In February 2014, the Company completed its IPO in which it issued and sold 1,430,000 shares of its common stock at a public offering price of $7.00 per share. The Company received net proceeds of $7,403 after deducting underwriting discounts and commissions of $848 and other offering expenses of approximately $1,759. The Company incurred $648 of the offering expenses in 2013, and incurred $1,959 of such expenses in the first quarter of 2014. Upon the closing of the IPO, all shares of the Company’s then-outstanding Series A convertible Preferred Stock (1,468,402), Series A-1 convertible Preferred Stock (293,750) and Series A-2 convertible Preferred Stock (250,000) automatically converted into an aggregate of 2,012,152 shares of common stock.

In February 2015, the Company completed a private placement in which it issued and sold 55,000 shares of its common stock at a price of $4.52 per share. The Company received proceeds of $248. In March 2015, the Company completed a private placement in which it issued and sold 62,500 shares of its common stock at a price of $4.00 per share. The Company received proceeds of $250. In April 2015, the Company completed a private placement in which it issued and sold 143,000 shares of its common stock at a price of $3.50 per share. The Company received proceeds of $501. In December 2015, the Company completed a private placement in which it issued and sold 140,000 shares of its common stock and warrants to purchase 28,000 shares of its common stock in exchange for proceeds of $374.

Voting Rights of Common Stock

Each holder of shares of Common Stock is entitled to one vote for each share held.

Common Stock Warrants

In February 2014, in connection with the closing of the IPO, the Company’s then outstanding warrants to acquire an aggregate of 1,067,210 shares of Series A convertible Preferred Stock and 228,656 shares of Series A-1 convertible Preferred Stock were cashlessly exercised at the IPO price for an aggregate of 479,115 shares of common stock. All other then outstanding warrants of the Company became exercisable for 288,214 shares of common stock effective upon the IPO in accordance with their terms. In addition, the Company issued the underwriter for its IPO warrants to acquire an aggregate of 71,500 shares of its common stock at an exercise price of $8.75 per share, which become exercisable February 20, 2015 and expire February 20, 2019.

In September 2015, the Company amended the terms of all of its outstanding warrants to acquire shares of its common stock (other than the underwriter warrants to acquire an aggregate of 71,500 shares) to provide that all such warrants expire July 31, 2023. The Company has recorded an expense of $363 as it relates to stock based compensation during the year ended December 31, 2015 for this change in expiration terms.

In December 2015, in connection with the closing of a private placement described above, the Company sold a 2-year warrant to acquire 28,000 shares of common stock at an exercise price of $1.75 per share.

Common Stock

For the years ended December 31, 2015 and 2014, a total of 2,297,625 and 1,009,214 shares of common stock, respectively, were reserved for issuance upon (i) exercise of common stock warrants, and (ii) the exercise of outstanding stock options, as follows:

	Year ended December 31,
	2015		2014
Common stock warrants		387,714		359,714
Options		1,909,911		649,500
Total		2,297,625		1,009,214

Offering Costs Associated With IPO

During the year ended December 31, 2014 the Company incurred a total of $1,959 of offering costs associated with IPO efforts all of which have been paid as of the date of this report.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Stock Option Plan

12 Months Ended

Dec. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Option Plan

10.

Stock Option Plan

The Company’s stock-based compensation program is designed to attract and retain employees while also aligning employees' interests with the interests of its stockholders. Stock options have been granted to employees under the stockholder-approved 2007 Key Person Stock Option Plan (“2007 Plan”) or the stockholder-approved 2014 Stock Incentive Plan (“2014 Plan”). Stockholder approval of the 2014 Plan became effective in September 2014. The 2014 Plan originally provided that the aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2014 Plan may not exceed 450,000 shares (the “Share Reserve”), however in October 2015, the stockholders approved a 1,500,000 increase to the Share Reserve. In addition, the Share Reserve automatically increases on January 1st of each year, for a period of not more than 10 years, beginning on January 1st of the year following the year in which the 2014 Plan became effective and ending on (and including) January 1, 2024, in an amount equal to 4% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Company’s Board of Directors may act prior to January 1st of a given year to provide that there will be no January 1st increase in the Share Reserve for such year or that the increase in the Share Reserve for such year will be a lesser number of shares of common stock than would otherwise occur. The Share Reserve is currently 2,138,640 shares for the year ending December 31, 2015.

In light of stockholder approval of the 2014 Plan, the Company no longer grants equity awards under the 2007 Plan. As of December 31, 2015, 0 shares of an aggregate total of 407,500 shares were available for future

stock-based compensation grants under the 2007 Plan and 621,179 shares of an aggregate total of 2,138,640 shares were available for future stock-based compensation grants under the 2014 Plan.

Aggregate intrinsic value represents the difference between the closing market value as of December 31, 2015 of the underlying common stock and the exercise price of outstanding, in-the-money options. A summary of the Company’s stock option activity and related information for 2015 and 2014 is as follows:

	Options Outstanding
	Number of Stock Options Outstanding			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (In Years)		Aggregate Intrinsic Value (in thousands)
Balance, January 1, 2014		337,500		$	0.52		6.16	$	2,693
Options granted		320,000			2.48
Options exercised		(8,000	)		0.52			$	17
Balance, December 31, 2014		649,500		$	1.49		7.44	$	474
Options granted		1,308,017			3.15
Options exercised		(7,051	)		2.10			$	17
Options forfeited/cancelled		(40,555	)		2.29
Balance, December 31, 2015		1,909,911		$	2.58		8.56	$	813
Exercisable as of December 31, 2014		399,552		$	1.10		6.01	$	474
Exercisable as of December 31, 2015		1,464,189		$	2.60		8.32	$	713

The total compensation cost related to unvested stock option awards not yet recognized was $771 and $332 as of December 31, 2015 and 2014, respectively. The weighted average period over which the total unrecognized compensation cost related to these unvested stock awards will be recognized is 3.0 years. The total estimated grant date fair value of options vested during the years ended December 31, 2015 and 2014 was $2,242 and $190, respectively. The weighted average grant date fair value of options granted during the year ended December 31, 2015 is $2.08 per share or an aggregate grant date fair value of $2,722. The weighted average grant date fair value of options granted during the year ended December 31, 2014 is $1.63 per share or an aggregate grant date fair value of $523. The weighted average grant date fair value of options forfeited during the year ended December 31, 2015 was $61. There were no forfeitures in 2014.

On July 24, 2014, the Company’s Board of Directors granted 70,000 stock options under the 2007 Plan. These options were 100% vested and exercisable at the date of issue. The Company recorded $178 of stock based compensation expense associated with these grants. During 2014, there were 70,000 grants, 8,000 exercised, no forfeitures, and no cancelations of stock options under the 2007 Plan.

On November 11, 2014, the Company’s Board of Directors granted options to acquire an aggregate of 250,000 shares under the 2014 Plan. The options vest monthly over 48 months such that they are vested in full on the four-year anniversary of the grant date. The Company has recorded $12 of stock based compensation expense associated with these grants.

On January 1, 2015, the Company’s Board of Directors granted an option to acquire an aggregate of 75,000 shares under the 2014 Plan. On May 1, 2015 the Company’s Board of Directors granted options to acquire an aggregate of 50,000 shares under the 2014 Plan. On July 21, 2015, the Company’s Compensation Committee granted options to acquire an aggregate of 111,300 shares under the 2014 Plan. All of these options vest monthly over 48 months such that they are vested in full on the four-year anniversary of the grant date.

On July 21, 2015, the Company’s Compensation Committee approved the grant of options to acquire an aggregate of 730,500 shares under the 2014 Plan, contingent upon receipt of stockholder approval of an increase of 1,500,000 shares in the 2014 Plan Share Reserve (which approval was received on October 29, 2015). These

options originally vested monthly over 12 months such that they are vested in full on the one-year anniversary of the October 29, 2015 grant effectiveness date. Then, on July 31, 2015, the Company’s Compensation Committee granted options to the Board of Directors to acquire an aggregate of 35,000 shares under the 2014 Plan, which options vested in full on the grant date.

On December 31, 2015, the Company’s Compensation Committee granted options to the Board of Directors to acquire an aggregate of 306,217 shares under the 2014 plan. Of these, 106,800 options vest monthly over 48 months such that they are vested in full on the four-year anniversary of the grant date. The remaining 199,417 options vested immediately upon grant. As of December 31, 2015 there were 1,558,017 grants, 7,051 exercises, 40,555 forfeitures and cancellations of stock options under the 2014 Plan.

In December 2015, the Company accelerated the vesting on 730,500 outstanding options such that they were vested in full as of December 31, 2015. The Company has recorded an expense of $1,062 as it relates to stock based compensation during the year ended December 31, 2015 for this change in vesting schedule.

Determining the Fair Value of Stock Options

The Company uses the Black-Scholes pricing model to determine the fair value of stock options. The fair value of each option grant is estimated on the date of the grant. The fair value of the options granted is estimated on the date of grant using the Black-Scholes pricing model and the following assumptions for the periods presented:

	Year ended December 31,
	2015			2014
Expected term (in years)		5			5
Risk-free interest rate		1.5 – 1.76	%		1.6 – 1.67	%
Expected volatility		80.7 – 83.3	%		82.2 – 83.0	%
Expected dividend rate		0	%		0	%

The assumptions are based on the following for each of the years presented:

Valuation Method — The Company estimates the fair value of its stock options using the Black-Scholes option pricing model.

Expected Term — The Company estimates the expected term consistent with the simplified method identified by the Securities and Exchange Commission (“SEC”). The Company elected to use the simplified method because of its limited history of stock option exercise activity and its stock options meet the criteria of the “plain-vanilla” options as defined by the SEC. The simplified method calculates the expected term as the average of the vesting and contractual terms of the award.

Volatility — Because the Company has limited trading history by which to determine the volatility of its own common stock price, the expected volatility being used is derived from the historical stock volatilities of a representative industry peer group of comparable publicly listed companies over a period approximately equal to the expected term of the options.

Risk-free Interest Rate — The risk-free interest rate is based on median U.S. Treasury zero coupon issues with remaining terms similar to the expected term on the options.

Expected Dividend — The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, used an expected dividend yield of zero in the valuation model.

Forfeiture — The Company estimates forfeitures at the time of grant and revises those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting forfeitures and records stock-based compensation expense only for those awards that are expected to vest. All stock-based payment awards are amortized on a straight-line basis over the

requisite service periods of the awards, which are generally the vesting periods. If the Company’s actual forfeiture rate is materially different from its estimate, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period.

The Company has recorded an expense of $2,605 and $190 as it relates to stock-based compensation for the years ended December 31, 2015 and 2014, respectively, which was allocated as follows based on the role and responsibility of the recipient in the Company:

	Year ended December 31,
	2015		2014
Cost of Revenue	$	2	$	1
Engineering and Product Development		101		1
Sales and Marketing		1,172		4
General and Administrative		1,330		184
Total	$	2,605	$	190

Income Taxes

12 Months Ended

Dec. 31, 2015

Income Tax Disclosure [Abstract]

Income Taxes

11.

Income Taxes

The components of the provision for income taxes are as follows:

	2015		2014
Current tax provision:
Federal	$	—	$	—
State		6		9
Deferred tax provision:
Federal		—		—
State		—		—
Total	$	6	$	9

A summary of the differences between the Company’s effective income tax rate and the Federal statutory income tax rate for the years ended December 31, 2015 and 2014 is as follows:

	2014			2013
Federal statutory rate		34.00	%		34.00	%
State income tax rate, net of federal benefit		(0.05	)%		(0.13	)%

Change in valuation allowance		(33.95	)%		(33.62	)%
Other		(0.07	)%		(0.45	)%
Effective income tax rate		(0.07	)%		(0.20	)%

Deferred tax assets are comprised of the following at December 31:

	2015			2014
Deferred tax assets:
Net operating loss carryforwards	$	4,732		$	2,966
Deferred Revenue		453			233
Depreciation and amortization		18			47
Stock-based compensation		1,105			163
Accrual and reserve		132			25
Research and Development Credits		130			106
Total gross deferred tax assets		6,570			3,540
Less valuation allowance		(6,570	)		(3,540	)
Net deferred tax assets	$	—		$	—

As of December 31, 2015, the Company has net operating loss carryforwards of approximately $13,400 for Federal and $4,800 for California, which begin to expire in 2032. The Company also has Federal research and development credit carryforwards of approximately $100 at December 31, 2015 which begin to expire in 2032.

ASC 740-10, Income Taxes, prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return and also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.

The Company’s ability to use operating loss carryforwards and tax credits to offset future taxable income is subject to restrictions under Section 382 of the United States Internal Revenue Code (the “Internal Revenue Code”). These restrictions may limit the future use of future operating loss carryforwards and tax credits if certain ownership changes described in the Internal Revenue Code occur. The Company’s pre-IPO net operating losses and tax credits are limited under Internal Revenue Code Section 382 as a result of an ownership change defined under Section 382. Future changes in stock ownership may occur that would create further limitations on the Company’s use of its operating loss carryforwards and tax credits. In such a situation, the Company may be required to pay income taxes, even though significant operating loss carryforwards and tax credits might exist.

As of December 31, 2015 and 2014, the Company had no unrecognized tax benefits and no adjustments to liabilities or operations were required for uncertain tax positions under ASC 740-10. The Company’s practice is to recognize interest and penalty expenses related to uncertain tax positions in income tax expense, which was zero for the years ended December 31, 2015 and 2014. The Company files income tax returns in the U.S. federal and several state tax jurisdictions.

The Company’s tax years beginning 2012 remain open for examination by the federal and state tax authorities for three and four years, respectively. Tax years beginning 2012 will remain open for examination from the date of utilization of any net operating loss or credits. The Company does not have any tax positions for which it is reasonably possible the total amount of gross unrecognized tax benefits will increase or decrease within 12 months of the year-ended December 31, 2015.

Net loss per share attributable to common stockholders

12 Months Ended

Dec. 31, 2015

Earnings Per Share [Abstract]

Net loss per share attributable to common stockholders

12.

Net loss per share attributable to common stockholders

The following table presents the calculation of basic and diluted net loss per share:

	Year ended December 31,
	2015			2014
Net loss	$	(8,501	)	$	(4,515	)
Weighted average shares outstanding		4,928,881			4,105,754
Basic and diluted loss per share attributable to common stockholders	$	(1.72	)	$	(1.10	)

Because the Company was in a loss position for each of the periods presented, diluted net loss per share is the same as basic net loss per share for each period as the inclusion of all potential common shares outstanding would have been anti-dilutive. The following weighted average shares outstanding of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been anti-dilutive:

	Year ended December 31,
	2015		2014
Weighted average shares outstanding:
Convertible preferred stock		—		—
Convertible preferred stock warrants		—		—
Common stock warrants		359,868		304,373
Options		1,122,197		403,662
Total		1,482,065		708,035

Subsequent Events

12 Months Ended

Dec. 31, 2015

Subsequent Events [Abstract]

Subsequent Events

13.

Subsequent Events

On January 15, 2016, the Company entered into a loan agreement with Chang Family Trust. Pursuant to the loan agreement, the Company obtained a $1,000 unsecured loan for a 24-month term that had a fixed interest rate of 10% p.a. Under the loan agreement, the Company will make one payment consisting of $1,000 of principal plus all accrued interest. Chang Family Trust was issued a warrant to purchase 114,286 shares of common stock at a strike price of $1.75 per share associated with this loan. As of the date of this filing, the Company is in compliance with all terms of this loan.

On January 15, 2016, the Company entered into a loan agreement with Chang Family Trust. Pursuant to the loan agreement, the Company obtained a $500 unsecured loan for a 24-month term that had a fixed interest rate of 5% p.a. Under the loan agreement, the Company will make one payment consisting of $500 of principal plus all accrued interest. Chang Family Trust was issued a warrant to purchase 114,286 shares of common stock at a strike price of $1.75 per share associated with this loan. As of the date of this filing, the Company is in compliance with all terms of this loan.

Summary of Significant Accounting Policies and Estimates (Policies)

12 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Basis for Presentation

Basis for Presentation

The Company’s financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Initial Public Offering

Initial Public Offering

Use of Estimates

Use of Estimates

Revenue Recognition

Revenue Recognition

Restricted Cash

Restricted Cash

Accounts Receivable and Allowance for Doubtful Accounts

Accounts Receivable and Allowance for Doubtful Accounts

Assets for Lease

Assets for Lease

Property and Equipment

Property and Equipment

At December 31, 2015 and 2014, capital assets are classified into one of the following categories:

	Category Name	Description
	Machinery & Equipment	Manufacturing, R&D, or other non-office equipment
	Computer Equipment & Software	Software, computers, monitors, printers and other related equipment.
	Furniture & Fixtures	Office equipment and furniture owned by the company

At December 31, 2015 and 2014, capital assets are depreciated based on the following assumed useful life for each category:

	Account Name	Useful Life
	Machinery & Equipment	Five years
	Computer Equipment & Software	Three years
	Furniture & Fixtures	Five years

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Level 1 — Unadjusted quoted prices in active markets for identical assets or liabilities;

Level 3 — Unobservable inputs that are supported by little or no market activity, which requires the Company to develop its own models.

Deferred Revenue

Deferred Revenue

Deferred Financing Costs

Deferred Financing Costs

Research and Development

Research and Development

Stock-Based Compensation

Stock-Based Compensation

Employee Benefit Plan

Employee Benefit Plan

Income Taxes

Income Taxes

Presentation of Prior Year Data

Presentation of Prior Year Data

Certain reclassifications have been made to conform prior year data to the current presentation.

Net Loss per Share

Net Loss per Share

Excise Tax Liability on Medical Devices

Excise Tax Liability on Medical Devices

Stock Option Plan (Tables)

12 Months Ended

Dec. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of summary of stock-based compensation activity

	Options Outstanding
	Number of Stock Options Outstanding			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (In Years)		Aggregate Intrinsic Value (in thousands)
Balance, January 1, 2014		337,500		$	0.52		6.16	$	2,693
Options granted		320,000			2.48
Options exercised		(8,000	)		0.52			$	17
Balance, December 31, 2014		649,500		$	1.49		7.44	$	474
Options granted		1,308,017			3.15
Options exercised		(7,051	)		2.10			$	17
Options forfeited/cancelled		(40,555	)		2.29
Balance, December 31, 2015		1,909,911		$	2.58		8.56	$	813
Exercisable as of December 31, 2014		399,552		$	1.10		6.01	$	474
Exercisable as of December 31, 2015		1,464,189		$	2.60		8.32	$	713

Schedule of weighted-average Black-Scholes fair value assumptions

	Year ended December 31,
	2015			2014
Expected term (in years)		5			5
Risk-free interest rate		1.5 – 1.76	%		1.6 – 1.67	%
Expected volatility		80.7 – 83.3	%		82.2 – 83.0	%
Expected dividend rate		0	%		0	%

Schedule of stock-based compensation based on the role and responsibility of the recipient in the Company

	Year ended December 31,
	2015		2014
Cost of Revenue	$	2	$	1
Engineering and Product Development		101		1
Sales and Marketing		1,172		4
General and Administrative		1,330		184
Total	$	2,605	$	190

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2015

Income Tax Disclosure [Abstract]

Schedule of components of the provision for income taxes

	2015		2014
Current tax provision:
Federal	$	—	$	—
State		6		9
Deferred tax provision:
Federal		—		—
State		—		—
Total	$	6	$	9

Schedule of differences between the Company's effective income tax rate and the Federal statutory income tax rate

	2014			2013
Federal statutory rate		34.00	%		34.00	%
State income tax rate, net of federal benefit		(0.05	)%		(0.13	)%

Change in valuation allowance		(33.95	)%		(33.62	)%
Other		(0.07	)%		(0.45	)%
Effective income tax rate		(0.07	)%		(0.20	)%

Schedule of deferred tax assets

	2015			2014
Deferred tax assets:
Net operating loss carryforwards	$	4,732		$	2,966
Deferred Revenue		453			233
Depreciation and amortization		18			47
Stock-based compensation		1,105			163
Accrual and reserve		132			25
Research and Development Credits		130			106
Total gross deferred tax assets		6,570			3,540
Less valuation allowance		(6,570	)		(3,540	)
Net deferred tax assets	$	—		$	—

Net loss per share attributable to common stockholders (Tables)

12 Months Ended

Dec. 31, 2015

Earnings Per Share [Abstract]

Schedule of basic and diluted net loss per share

	Year ended December 31,
	2015			2014
Net loss	$	(8,501	)	$	(4,515	)
Weighted average shares outstanding		4,928,881			4,105,754
Basic and diluted loss per share attributable to common stockholders	$	(1.72	)	$	(1.10	)

Schedule of common stock equivalents excluded from the computation of diluted net loss per share

	Year ended December 31,
	2015		2014
Weighted average shares outstanding:
Convertible preferred stock		—		—
Convertible preferred stock warrants		—		—
Common stock warrants		359,868		304,373
Options		1,122,197		403,662
Total		1,482,065		708,035

Going Concern (Detail Textuals) - USD ($) $ in Thousands	Dec. 31, 2015	Jan. 01, 2015	Dec. 31, 2014	Dec. 31, 2013
Going Concern [Abstract]
Working capital	$ 2,356
Cash	405	$ 4,156	$ 4,156	$ 734
Restricted cash			2,100
Stockholders equity	$ (1,072)	$ 3,436	$ 3,436	$ (295)

Summary of Significant Accounting Policies and Estimates (Detail Textuals) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Feb. 28, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Summary Of Significant Accounting Policies And Estimates [Line Items]
Aggregate number of common stock shares exercisable at initial public offering	479,115
Series A convertible Preferred Stock
Summary Of Significant Accounting Policies And Estimates [Line Items]
Number of common stock called by warrants	1,067,210
Number of preferred stocks shares converted	1,468,402
Series A-1 convertible Preferred Stock
Summary Of Significant Accounting Policies And Estimates [Line Items]
Number of preferred stocks shares converted	293,750
Number of shares issued for conversion of preferred stock	228,656
Series A-2 convertible Preferred Stock
Summary Of Significant Accounting Policies And Estimates [Line Items]
Number of preferred stocks shares converted	250,000
Common Stock
Summary Of Significant Accounting Policies And Estimates [Line Items]
Number of common stock shares issued and sold				1,430,000
Number of preferred stocks shares converted				2,491,267
Initial public offering
Summary Of Significant Accounting Policies And Estimates [Line Items]
Number of common stock shares issued and sold	1,430,000
Public offering price (in dollars per share)	$ 7.00			$ 7.00
Net proceeds from initial public offering	$ 7,403
Underwriting discounts and commissions	848
Other offering expenses	$ 1,759
Offering expenses		$ 1,959	$ 1,959		$ 648
Initial public offering \| Common Stock
Summary Of Significant Accounting Policies And Estimates [Line Items]
Number of shares issued for conversion of preferred stock	2,012,152
Aggregate number of common stock shares exercisable at initial public offering	479,115
Underwriters option
Summary Of Significant Accounting Policies And Estimates [Line Items]
Number of additional shares acquire	214,500
Number of common stock called by warrants	71,500
Exercise price per warrants	$ 8.75

Summary of Significant Accounting Policies and Estimates (Detail Textuals 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Minimum percentage for cash balance of collateral cash account on line of credit	105.00%
Description of assets for lease	assets for lease is depreciated on a straight-line basis over 36 months for the units outstanding and recorded as cost of revenue
Fair value of warrants exercisable for common stock at issuance	$ 425
Amortized interest expense	$ 55	$ 147
Machinery & Equipment
Property, Plant and Equipment [Line Items]
Capital assets depreciated assumed useful life	Five years
Computer Equipment & Software
Property, Plant and Equipment [Line Items]
Capital assets depreciated assumed useful life	Three years
Furniture & Fixtures
Property, Plant and Equipment [Line Items]
Capital assets depreciated assumed useful life	Five years

Assets for lease, net - Summary of assets for lease (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Leases, Capital [Abstract]
Assets for lease	$ 1,280	$ 956
Less: accumulated depreciation	(450)	(283)
Assets for lease, net	$ 830	$ 673

Property and Equipment, net (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Capital assets	$ 542	$ 13
Less: accumulated depreciation	(45)	(4)
Capital assets, net	$ 497	$ 9

Accrued Expenses - Summary of accrued expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Accrued Liabilities, Current [Abstract]
Offering Costs	$ 227	$ 407
Compensation	1,093	721
Miscellaneous Accruals	997	235
Total Accrued Expenses	$ 2,317	$ 1,363

Concentration of Credit Risk (Detail Textuals) $ in Thousands	12 Months Ended
	Dec. 31, 2015 USD ($) Customer	Dec. 31, 2014 USD ($) Customer
Concentration Risk [Line Items]
Reserve against its accounts receivable \| $	$ 183	$ 51
Sales revenue \| Customer concentration risk
Concentration Risk [Line Items]
Number of customers	2	2
Sales revenue \| Customer concentration risk \| Customer one concentration risk
Concentration Risk [Line Items]
Concentration risk percentage	14.20%	12.90%
Sales revenue \| Customer concentration risk \| Customer two concentration risk
Concentration Risk [Line Items]
Concentration risk percentage	11.80%	11.70%
Significant invoicing \| Customer concentration risk
Concentration Risk [Line Items]
Number of customers	2	2
Significant invoicing \| Customer concentration risk \| Customer one concentration risk
Concentration Risk [Line Items]
Concentration risk percentage	18.60%	19.80%
Significant invoicing \| Customer concentration risk \| Customer two concentration risk
Concentration Risk [Line Items]
Concentration risk percentage	11.70%	12.10%
Accounts receivable \| Customer concentration risk
Concentration Risk [Line Items]
Number of customers	2	3
Accounts receivable \| Customer concentration risk \| Customer one concentration risk
Concentration Risk [Line Items]
Concentration risk percentage	19.40%	31.40%
Accounts receivable \| Customer concentration risk \| Customer two concentration risk
Concentration Risk [Line Items]
Concentration risk percentage	13.30%	13.20%
Accounts receivable \| Customer concentration risk \| Customer three concentration risk
Concentration Risk [Line Items]
Concentration risk percentage		10.30%

Commitments and Contingencies (Detail Textuals) - USD ($)		1 Months Ended	12 Months Ended
	Jul. 15, 2015	Sep. 23, 2014	Dec. 31, 2015
Property Subject to or Available for Operating Lease [Line Items]
Future lease payments for December 31, 2016			$ 188,600
Future lease payments for December 31, 2017			194,400
Future lease payments for December 31, 2018			16,500
Accrued rent			50,000
Facilities lease expense			209,000
Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Term specified for lease agreement		36 months
Future lease payments for December 31, 2016			209,100
Future lease payments for December 31, 2017			215,400
Future lease payments for December 31, 2018			18,000
Sub Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Term specified for lease agreement	30 months
Lease term from February 2015 to January 2016 \| Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Payments required per month under terms of lease agreement			17,000
Lease term from February 2016 to January 2017 \| Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Payments required per month under terms of lease agreement			17,500
Lease term from February 2017 to January 2018 \| Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Payments required per month under terms of lease agreement			18,000
Lease term from August 2015 to July 2016 \| Sub Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Payments required per month under terms of lease agreement			15,500
Lease term from August 2016 to July 2017 \| Sub Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Payments required per month under terms of lease agreement			16,000
Lease term from August 2017 to July 2018 \| Sub Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Payments required per month under terms of lease agreement			$ 16,500

Commitments and Contingencies (Detail Textuals 1) - USD ($) $ in Thousands			1 Months Ended			12 Months Ended
	Sep. 13, 2011	Feb. 09, 2011	Sep. 30, 2014	Jun. 17, 2011	May. 27, 2011	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2011
Commitments And Contingencies [Line Items]
Restricted cash							$ 2,100
Interest expense						$ 19	$ 28
Secured Debt \| Equipment Finance Agreement \| U.S. Bancorp Business Equipment Finance Group